Her3 - Network of Cancer Research

Izalontamab (SI-B001) is a Bispecific Anti-EGFR/HER3 mAb for Cancer Research

Louis Gilman March 15, 2023

EGFR (epidermal growth factor receptor) is a member of the ErbB receptor family1. Besides, EGFR is a common therapeutic strategy in epithelioma such as lung adenocarcinoma, colon cancer, head and…

Breast Cancer Non-Small Cell Lung Cancer

TX1-85-1, a ATP-competitive ligand of Her3, covalent modification of Her3 to inhibit Her3 signaling

Louis Gilman June 1, 2019

Her3 (also known as ErbB3) is a member of the epidermal growth factor receptor (EGFR) tyrosine kinases, including Her1, Her2 and Her4. However, owing to receptor or ligand overexpression or…

Izalontamab (SI-B001) is a Bispecific Anti-EGFR/HER3 mAb for Cancer Research

TX1-85-1, a ATP-competitive ligand of Her3, covalent modification of Her3 to inhibit Her3 signaling

You Missed

BI 7446 is a STING Agonist for Immuno-oncology Research

JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research

OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research

INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research